PE20210121A1 - Regimenes de dosificacion superior de g1t38 - Google Patents

Regimenes de dosificacion superior de g1t38

Info

Publication number
PE20210121A1
PE20210121A1 PE2020000908A PE2020000908A PE20210121A1 PE 20210121 A1 PE20210121 A1 PE 20210121A1 PE 2020000908 A PE2020000908 A PE 2020000908A PE 2020000908 A PE2020000908 A PE 2020000908A PE 20210121 A1 PE20210121 A1 PE 20210121A1
Authority
PE
Peru
Prior art keywords
provides
dosage regimen
solid
dose
auc
Prior art date
Application number
PE2020000908A
Other languages
English (en)
Inventor
Andrew Beelen
Jay Copeland Strum
Original Assignee
G1 Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by G1 Therapeutics Inc filed Critical G1 Therapeutics Inc
Publication of PE20210121A1 publication Critical patent/PE20210121A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invencion se refiere a un regimen de dosificacion para la administracion del inhibidor selectivo de CDK4/6 conocido como G1T38, que es 2'-((5-(4-isopropilpiperazin-1-il)piridin-2-il)amino)-7',8'-dihidro-6'H-espiro[ciclohexano-1,9'-pirazino[1',2':1,5]pirrolo[2,3-d]pirimidin]-6'-ona o una sal farmaceuticamente aceptable del mismo y se emplea en el tratamiento de diversos tipos de cancer. Este regimen de dosificacion suministra: a) un regimen de dosificacion solido de G1T38 para el suministro oral que proporciona una relacion de (AUC(0-24ss) media en estado estacionario (h ng/mL))/dosis (mg) no mayor que 5 y/o b) un regimen de dosificacion solido de G1T38 para el suministro oral que en el dia 22 despues de la primera dosis proporciona una relacion AUC (0-24ss) media en estado estacionario (h ng/mL)/recuento absoluto de neutrofilos (celulas/mm3) no mayor que 1,25.
PE2020000908A 2018-01-08 2019-01-08 Regimenes de dosificacion superior de g1t38 PE20210121A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862614952P 2018-01-08 2018-01-08
US201862679575P 2018-06-01 2018-06-01
US201962788017P 2019-01-03 2019-01-03
PCT/US2019/012720 WO2019136451A1 (en) 2018-01-08 2019-01-08 G1t38 superior dosage regimes

Publications (1)

Publication Number Publication Date
PE20210121A1 true PE20210121A1 (es) 2021-01-19

Family

ID=67143921

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2020000908A PE20210121A1 (es) 2018-01-08 2019-01-08 Regimenes de dosificacion superior de g1t38

Country Status (15)

Country Link
US (2) US11357779B2 (es)
EP (1) EP3738084A4 (es)
JP (1) JP2021509680A (es)
KR (1) KR20200108867A (es)
CN (1) CN111837146A (es)
BR (1) BR112020013915A2 (es)
CA (1) CA3087570A1 (es)
CO (1) CO2020008825A2 (es)
IL (1) IL275708A (es)
MX (1) MX2020007312A (es)
PE (1) PE20210121A1 (es)
PH (1) PH12020551050A1 (es)
RU (1) RU2020123665A (es)
SG (1) SG11202005937QA (es)
WO (1) WO2019136451A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108434149B (zh) * 2013-03-15 2021-05-28 G1治疗公司 针对Rb阳性异常细胞增殖的HSPC节制性治疗
TWI823845B (zh) 2017-01-06 2023-12-01 美商G1治療公司 用於治療癌症的組合療法
WO2019199883A1 (en) * 2018-04-09 2019-10-17 G1 Therapeutics, Inc. Treatment of cancers having driving oncogenic mutations
TW202128174A (zh) * 2019-10-09 2021-08-01 美商G1治療公司 失調之纖維母細胞生長因子受體訊息傳遞的癌症之標靶性治療
IL298294A (en) 2020-05-19 2023-01-01 G1 Therapeutics Inc Cyclin-dependent kinase inhibitory compounds for the treatment of medical disorders
KR20230057384A (ko) * 2020-08-13 2023-04-28 화이자 인코포레이티드 조합 요법
CA3212705A1 (en) * 2021-03-17 2022-09-22 Amgen Inc. Sotorasib dosing regimen

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1740184A1 (en) 2004-03-30 2007-01-10 Pfizer Products Incorporated Combinations of signal transduction inhibitors
WO2006061712A2 (en) * 2004-12-10 2006-06-15 Pfizer Inc. Use of mek inhibitors in treating abnormal cell growth
AU2007336933A1 (en) 2006-12-22 2008-07-03 Novartis Ag Heteroaryl-heteroaryl compounds as CDK inhibitors for the treatment of cancer, inflammation and viral infections
WO2009061345A2 (en) 2007-11-07 2009-05-14 Cornell Research Foundation, Inc. Targeting cdk4 and cdk6 in cancer therapy
CN101945867A (zh) 2007-12-19 2011-01-12 安姆根有限公司 作为细胞周期抑制剂的稠合吡啶、嘧啶和三嗪化合物
JP5579715B2 (ja) 2008-07-29 2014-08-27 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ ｃｄｋ阻害剤および抗悪性腫瘍剤を含む治療用組合せ
KR101353857B1 (ko) 2008-08-22 2014-01-21 노파르티스 아게 Ｃｄｋ 억제제로서 피롤로피리미딘 화합물
US20110224221A1 (en) 2008-10-01 2011-09-15 Sharpless Norman E Hematopoietic protection against ionizing radiation using selective cyclin-dependent kinase 4/6 inhibitors
EP2341911A4 (en) 2008-10-01 2012-10-24 Univ North Carolina HEMATOPOIETIC PROTECTION AGAINST CHEMOTHERAPEUTIC COMPOUNDS USING SELECTIVE INHIBITORS OF KINASES DEPENDENT ON CYCLINES 4/6
PA8852901A1 (es) 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
ES2561216T3 (es) 2009-05-13 2016-02-25 The University Of North Carolina At Chapel Hill Inhibidores de cinasas dependientes de ciclina y procedimientos de uso
EP2536752B1 (en) * 2010-02-16 2015-04-08 Novo Nordisk A/S Modified recombinant Factor VIII
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
UY33226A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
US8691830B2 (en) 2010-10-25 2014-04-08 G1 Therapeutics, Inc. CDK inhibitors
EP3567042B1 (en) 2010-10-25 2021-07-07 G1 Therapeutics, Inc. Cdk inhibitors
CA2818046A1 (en) 2010-11-17 2012-05-24 The University Of North Carolina At Chapel Hill Protection of renal tissues from ischemia through inhibition of the proliferative kinases cdk4 and cdk6
DK2937349T3 (en) 2011-03-23 2017-02-20 Amgen Inc CONDENSED TRICYCLIC DUAL INHIBITORS OF CDK 4/6 AND FLT3
JP5832647B2 (ja) 2011-07-01 2015-12-16 ノバルティス アーゲー がんの治療における使用のためのｃｄｋ４／６阻害剤およびｐｉ３ｋ阻害剤を含む併用療法
MY161925A (en) 2011-07-27 2017-05-15 Astrazeneca Ab 2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer
EP2831080B1 (en) 2012-03-29 2017-03-15 Francis Xavier Tavares Lactam kinase inhibitors
AR091876A1 (es) 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
CA2880764C (en) 2012-08-03 2022-08-30 Foundation Medicine, Inc. Human papilloma virus as predictor of cancer prognosis
WO2014144596A2 (en) 2013-03-15 2014-09-18 G1 Therapeutics, Inc. Transient protection of hematopoietic stem and progenitor cells against ionizing radiation
CN108434149B (zh) 2013-03-15 2021-05-28 G1治疗公司 针对Rb阳性异常细胞增殖的HSPC节制性治疗
CA2906157C (en) * 2013-03-15 2022-05-17 G1 Therapeutics, Inc. Highly active anti-neoplastic and anti-proliferative agents
CN106029099A (zh) 2013-08-28 2016-10-12 诺华股份有限公司 用于治疗细胞增殖性疾病的alk抑制剂与cdk抑制剂的组合
WO2015061407A1 (en) 2013-10-24 2015-04-30 Francis Xavier Tavares Process for synthesis of lactams
WO2015084892A1 (en) 2013-12-02 2015-06-11 Cornell University Methods for treating b cell proliferative disorders
JP6263269B2 (ja) 2013-12-31 2018-01-17 シュエンジュウ・ファーマ・カンパニー・リミテッド キナーゼ阻害剤及びその使用
WO2015161288A1 (en) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic lactams for use as anti-neoplastic and anti-proliferative agents
TW201618774A (zh) * 2014-08-11 2016-06-01 艾森塔製藥公司 使用ｂｔｋ抑制劑透過調變腫瘤微環境來治療實體腫瘤及其他疾病之方法
TW201618773A (zh) 2014-08-11 2016-06-01 艾森塔製藥公司 Ｂｔｋ抑制劑、ｐｉ３ｋ抑制劑、ｊａｋ－２抑制劑、及／或ｃｄｋ４／６抑制劑的治療組合物
WO2016040858A1 (en) * 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
WO2016040882A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies of egfr inhibitors
EP3200775B1 (en) 2014-10-03 2019-11-20 Novartis AG Combination therapies
WO2016126889A1 (en) * 2015-02-03 2016-08-11 G1 Therapeutics, Inc. Cdk4/6 inhibitor dosage formulations for the protection of hematopoietic stem and progenitor cells during chemotherapy
JP2018526376A (ja) 2015-08-28 2018-09-13 ノバルティス アーゲー がんの治療または予防のための（ａ）サイクリン依存性キナーゼ４／６（ｃｄｋ４／６）阻害剤のｌｅｅ０１１（＝リボシクリブ）および（ｂ）上皮成長因子受容体（ｅｇｆｒ）阻害剤のエルロチニブを含む医薬組み合わせ物
WO2017160568A1 (en) 2016-03-16 2017-09-21 Eli Lilly And Company Combination therapy comprising the cdk4/6 inhibitor necitumumab and the egfr inhibitor abemaciclib for use in treating cancer
WO2017193141A1 (en) 2016-05-06 2017-11-09 Siyuan Zhang Prognosis biomarkers and anti-tumor compositions of targeted therapeutic treatments for triple negative breast cancer
EP4066827A1 (en) 2016-06-22 2022-10-05 Ellipses Pharma Ltd Ar+ breast cancer treatment methods
EP3503923B1 (en) 2016-08-23 2023-10-04 Eisai R&D Management Co., Ltd. Combination therapies for the treatment of hepatocellular carcinoma
WO2018089518A1 (en) 2016-11-08 2018-05-17 Dana-Farber Cancer Institute, Inc. Compositions and methods of modulating anti-tumor immunity
US20190275049A1 (en) 2016-11-16 2019-09-12 Pfizer Inc. Combination of an EGFR T790M Inhibitor and a CDK Inhibitor for the Treatment of Non-Small Cell Lung Cancer
CN110035759A (zh) 2016-12-05 2019-07-19 G1治疗公司 化疗方案期间免疫反应的保持
EP3585389A4 (en) 2017-02-22 2020-12-23 G1 Therapeutics, Inc. TREATMENT OF EGFR MEDIATED CANCER WITH LESS SIDE EFFECTS
AU2018234903B2 (en) 2017-03-16 2024-02-08 Eisai R&D Management Co., Ltd. Combination therapies for the treatment of breast cancer
CN111148518A (zh) 2017-03-30 2020-05-12 丹娜法伯癌症研究院 使用cdk4/6抑制剂调控调节性t细胞和免疫应答的方法
WO2018218633A1 (en) 2017-06-02 2018-12-06 Beijing Percans Oncology Co. Ltd. Combination therapies for treating cancers
AU2018282901A1 (en) 2017-06-12 2020-01-16 Syros Pharmaceuticals, Inc. Compositions and methods for treating cancers with covalent inhibitors of cyclin-dependent kinase 7 (CDK7)
GB201709417D0 (en) 2017-06-14 2017-07-26 Inst Of Cancer Research: Royal Cancer Hospital Cyclin dependent kinase 4/6 inhibitors for use in methods of treating cancer
US20200138804A1 (en) 2017-06-21 2020-05-07 X4 Pharmaceuticals, Inc. Methods for treating cancer
CN109982701B (zh) 2017-06-21 2022-04-12 江苏恒瑞医药股份有限公司 SERD与CDK4/6抑制剂、PI3K/mTOR通路抑制剂的用途
NZ759691A (en) * 2017-06-29 2023-05-26 G1 Therapeutics Inc Morphic forms of git38 and methods of manufacture thereof
SG11201913244QA (en) 2017-08-03 2020-02-27 Novartis Ag Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a cyclin d kinase inhibitor
US20200377599A1 (en) 2017-11-30 2020-12-03 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for treating cancer

Also Published As

Publication number Publication date
EP3738084A1 (en) 2020-11-18
RU2020123665A (ru) 2022-02-10
AU2019205821A1 (en) 2020-07-09
US11357779B2 (en) 2022-06-14
CO2020008825A2 (es) 2020-07-31
MX2020007312A (es) 2021-01-08
PH12020551050A1 (en) 2021-08-23
KR20200108867A (ko) 2020-09-21
SG11202005937QA (en) 2020-07-29
EP3738084A4 (en) 2021-11-17
WO2019136451A1 (en) 2019-07-11
IL275708A (en) 2020-08-31
US20200405721A1 (en) 2020-12-31
JP2021509680A (ja) 2021-04-01
BR112020013915A2 (pt) 2020-12-01
CA3087570A1 (en) 2019-07-11
CN111837146A (zh) 2020-10-27
US20230149406A1 (en) 2023-05-18

Similar Documents

Publication Publication Date Title
PE20210121A1 (es) Regimenes de dosificacion superior de g1t38
CN117562905A (zh) 化疗方案期间免疫反应的保持
Nonnenmacher et al. RIST: A potent new combination therapy for glioblastoma
JP2012180381A5 (es)
HRP20240082T1 (hr) Inhibitor pde9 s okosnicom imidazopirazinona za liječenje perifernih bolesti
US20140336180A1 (en) Combination of mek inhibitors and selective inhibitors of aurora a kinase
JP2017523207A5 (es)
JP2021510725A5 (es)
JP2017502013A5 (es)
JP2020512977A (ja) Ｃｈｋ１阻害剤とｗｅｅ１阻害剤との組み合わせ
ECSP11011403A (es) Derivado de benzodiazepina para el tratamiento de neoplasma hematopoyetico y leucemia
CN112867512A (zh) 联合疗法
RU2017134443A (ru) Способ лечения с применением традипитанта
CA2747326A1 (en) Combination of aurora kinase inhibitors and anti-cd20 antibodies
RU2391101C2 (ru) Комбинированное применение эктеинасцидина-743 и содержащих платину противоопухолевых соединений
JP2013209384A5 (es)
NZ630314A (en) Combination therapy for hematological malignancies
EA201992768A1 (ru) Морфологические формы g1t38 и способы их получения
CO2022008437A2 (es) Métodos de tratamiento del cáncer de pulmón de cé-lulas pequeñas con formulaciones de lurbinectedina
AR080737A1 (es) Uso de un inhibidor de la proteinquinasa c ( pkc)
MX2015009546A (es) Dosificacion aumentada de efavirenz para el tratamiento de cancer.
JP2019526559A5 (es)
JP2013540734A5 (es)
KR20070089158A (ko) 암의 치료를 위한ｎ-(3-메톡시-5-메틸피라진-2-일)-2-(4-[1,3,4-옥사디아졸-2-일]페닐)피리딘-3-설폰아미드 및 항-유사분열제의 조합물
CA2868024A1 (en) Methods of treating cancer using aurora kinase inhibitors